Phase 2 Prostate Cancer Trial, Recruiting (NCT06610825)

Phase 2 Prostate Cancer Trial, Recruiting NCT06610825 Sponsor: Washington D.C. Veterans Affairs Medical Center Condition: Prostate Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06610825 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Prostate Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You have been diagnosed with prostate cancer (specifically a type called adenocarcinoma) confirmed by a lab test
Your prostate cancer has spread to other parts of your body and is no longer responding to hormone treatments (this is called metastatic castration-resistant prostate cancer)
Your cancer has continued to grow despite treatment with hormone-blocking therapies, with or without having received chemotherapy
You are currently receiving treatment to keep your testosterone levels very low (below 50 ng/dL)
A stored tumor tissue sample is available for testing
You are expected to live at least 6 months
You are generally active and able to care for yourself (confirm with trial site for exact fitness level required)
Your heart is pumping blood effectively (at least 50% efficiency)
Your blood clotting, organ function, bone marrow, kidneys, and liver are all working well enough (confirm with trial site for exact requirements)

Who may not be able to join:

You have a history of a serious lung condition called interstitial lung disease, or lung inflammation (pneumonitis) that required steroid treatment
You have significant heart or coronary artery disease
You have previously received any treatment that specifically targeted HER2 (a type of protein found on some cancer cells)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Maneesh Jain, MD, Washington DC VA Medical Center

Phone: 2027431090

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06610825

Sponsor: Washington D.C. Veterans Affairs Medical Center

Phase: Phase 2

Status: Recruiting

Condition: Prostate Cancer

Trial contact: 2027431090

More information: https://clinicaltrials.gov/study/NCT06610825

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You have been diagnosed with prostate cancer (specifically a type called adenocarcinoma) confirmed by a lab test
Your prostate cancer has spread to other parts of your body and is no longer responding to hormone treatments (this is called metastatic castration-resistant prostate cancer)
Your cancer has continued to grow despite treatment with hormone-blocking therapies, with or without having received chemotherapy
You are currently receiving treatment to keep your testosterone levels very low (below 50 ng/dL)
A stored tumor tissue sample is available for testing
You are expected to live at least 6 months
You are generally active and able to care for yourself (confirm with trial site for exact fitness level required)
Your heart is pumping blood effectively (at least 50% efficiency)
Your blood clotting, organ function, bone marrow, kidneys, and liver are all working well enough (confirm with trial site for exact requirements)

Who may not be able to join:

You have a history of a serious lung condition called interstitial lung disease, or lung inflammation (pneumonitis) that required steroid treatment
You have significant heart or coronary artery disease
You have previously received any treatment that specifically targeted HER2 (a type of protein found on some cancer cells)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Washington D.C. Veterans Affairs Medical Center

Registry

ClinicalTrials.gov

Start date

5 March 2025

Est. completion

1 October 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

ORR

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov